Iziphumo zibonisa ukuba le nkunkuma inganciphisa isifo se-Alzheimer
Andiyithandi amanqaku okubhala malunga nesifo sengqondo kunye nesifo se-Alzheimer . Isifo se-Alzheimer sisifo esibuhlungu. Iyaqhubeka ngokukhawuleza. Izidakamizwa ezivunyiweyo ze-FDA ukunyangwa kwesi sifo njengo-Aricept, Nemenda, kunye noCognex abancinci ukuphucula inkcazo yekliniki.
Uninzi lwama-neurologists bayazi ukuba imishanguzo ayixabisekanga kakhulu kwizigulane ezine-Alzheimer's disease.
Nangona kunjalo, abathandekayo bacela la mayeza kunye nethemba lokuba le ngcamango inokunceda kwindlela encinane. Ekugqibeleni, unyango olungcono lwabantu abane-Alzheimer's disease ngumnyamekelo wokunyamekela ongeyena kuphela ogcina umgangatho wobomi bomntu lowo wesifo kodwa kunye nomgangatho wobomi kumntu onomnakekeli ngokwakhe.
Nangona ndandiphazamisa ngokubanzi ukubhala amanqaku malunga nesifo se-Alzheimer, ndivumelene nam ukuba ndifake esi sifo kuphela xa ityala lonyango lonyango libonisa ukunciphisa ukuncipha kwengqondo kubantu abanesifo. Kungekudala, iziphumo zakudala ezivela kwizilingo ezibandakanya i-adoganumab ye-Biogen ibonisa ukuba le nyi-antibody yodwa ingaphazamisa ukunyuka kwesifo se-Alzheimer's.
Isifo se-Alzheimer yindlela eqhelekileyo yengqondo. E-United States, kulinganiselwa ukuba izigidi ezingama-5 zaseMerika ezineminyaka engama-65 nangaphezulu zihlala nesi sifo. Isifundo se-Alzheimer's disease siphumeze kwaye singenakuphikiswa.
Ngokuhamba kwexesha, i-Alzheimers ikhumbuza imemori, ukucinga kunye nokuqiqa. Ekugqibeleni, umntu onesi sifo esibuhlungu esele akakwazi ukwenza ngisho nemisebenzi elula kunye nemisebenzi yokuphila kwansuku zonke.
Inkcazo yethu yangoku yokukhubazeka kwesifo se-Alzheimer igxininiswe kwi-"hypothesis" ye-amyloid . Ngokukodwa, i-neurodegeneration ibangelwa kwidiphozithi ye-amyloid-beta (Aß) iipepptide kwiiplanga zengqondo.
Ukuqokelela i-Aß iqhuba i-Alzheimer's disease pathogenesis. Enye into ebangela inxaxheba iquka i-neurofibrillary tangles eyenziwe ngeprotheni ye-tau. Ukungalingani phakathi kwe-Aß yokuvelisa kunye ne-Aß imvume kukukhokelela ekubunjweni kwezi ngqungquthela.
Kuza kube yimhla, i-bevy yamagciwane ahlukeneyo aphuhlisiwe ukulwa nesifo se-Alzheimer ngokujolisa i-amyloid. Ngokukodwa, i-aducanumab ye-antibody isebenza ngokubangela i-phagocytosis ye-Fc-receptor-mediator of Aß plaques. Ngamanye amazwi, i-aducanumab ivuselela i-phagocytes yomzimba wethu ukugaya i-Aß.
Kwiminyaka yakutshanje, "i-hypothesis" ye-"amyloid" ibuzwe ngokugqithiseleyo kwaye ibhalwe yinkwenkwezi ezininzi njengongqongqo. Asinakho ukuqinisekiswa kwekliniki kwiingcamango, kwaye abaninzi bakholelwa ukuba ukuqokelela i-Aß inokuba yinxalenye yenkqubo ebalulekileyo kunye engaqondakaliyo ebangela ukuba kungabonakali. Ngokukodwa, kulabo abane-Alzheimer's disease, i-Aß ibeka phambi kokunyuka kwengqondo ngeminyaka eyi-10 ukuya kwe-15 ngaloo ndlela ihlanganise isiluleko sobudlelwane obunobangela kunye nesiphumo. Ukongezelela, i-metabolism yeprotheni yeprotheni (i-APP) ayiphumeli kuphela i-Aß kodwa nezinye iinqununu ezingadlala indima kwi-pathogenesis ye-Alzheimer.
Ngokusekelwe kwiziphumo zesikhashana sesigaba se-Phase 1b yesilingo se-aducanumab esibizwa nge-PRIME, i-Biogen iye yenze isilingo seSigaba sesi-3 sonyango.
Nazi ezinye zeziphumo zesikhashana:
- Unyango kunye ne-aducanumab kubangele ukunciphisa iipliti ze-amyloid kubantu abane-prozromal okanye i-Alzheimer's disease.
- Ukunciphisa kwiiplathi kwakuboniswe ngeteknoloji ye-PET, kwaye le ncitshiseko yayingumthamo-kwaye kuxhomekeke kwixesha.
- Emva konyaka omnye unyango, abathathi-nxaxheba kwisifo sokuqala se-Alzheimer babonisa ukuphuculwa kweempawu ezinokliniki ekuphazamisekeni kwengqondo njengoko kufunyenwe yi-Mini-Mind mentation Examination (MMSE) kunye neCognitive Dementia Rating.
- Ukhuseleko kunye nokunyamezela komonde we-aducanumab kwamkelekile. Eminye imiphumo emibi yayibandakanya intloko kunye ne-ARIA (okungafaniyo kweengxelo ze-amyloid).
Ukuze isilwanyana se-Alzheimer okanye nawaphi na amachiza amasha ukuba avunywe yi-FDA, kufuneka idlule kwiZigaba ze-3 zezilingo. Njengoko kuchaziwe kwinqaku elandul 'ingxelo ebizwa ngokuthi "Iimvavanyo eziphambili ze-b-secretase inhibitors kwi-Alzheimers" ezivela kwi- Nature Biotechnology , abanye abavelisi beziyobisi bezilwanyana ze-Alzheimer bajonge kwiimvavanyo zeSigaba 3. Lo mkhuba unobungozi kuba iziphumo ezingabalulekanga kwiziphumo zeSigaba sesi-3 ziya kuvalwa ukuphuhliswa kweziyobisi. Emva koko, akukho mntu ufuna ukutshala imali kwi-"sitshiso".
Kungenxa yokuba isigqirha siphumelele ukubonisa iziphumo ezibalulekileyo zekliniki kwisinye isilingo esithile seSigaba sesi-3 asithethi ukuba le nkunkuma ayisebenzi. Ngokomzekelo, kunokwenzeka ukuba isilwanyana sinokusebenza kwimilinganiselo eyahlukileyo kulabo bavavanywa. Okanye, ezinye iziyobisi zisebenza kakuhle kwiindawo ezithile. Esikhundleni sokudlula iRubicon kunye nokuqhuba isilingo sesiGaba sesi-3, yinto efanelekileyo yokwenza uvavanyo lweSigaba sesi-2 nokuqonda kakuhle isibisi kunye nemiphumo yaso. Ngokwahlukileyo, i-Biogen inqume ukuqhubeka nezilingo zesigaba se-3 ngokukhawuleza izikhuthazo zesikhashana ukusuka kwi-test 1b.
Ukuba wena okanye othandekayo unesifo sesifo se-Alzheimer, nceda ufunde eli nqaku ngaphakathi kwimeko kwaye ungenalo ithemba lobuxoki. I-Biogene isesexesha elide ekutholeni imvume ye-aducanumab, kwaye sisadinga iziphumo ezininzi zeekliniki. Nangona iziphumo zakudala malunga ne-aducanumab zithembisa, iziyobisi ze-Alzheimer ziyaziwayo ngenxa yokuhluleka ukunqumla isardard, kwaye asikafumani unyango olululo ngokwenene olujoliswe ekunciphiseni ukuqhubela phambili kwesi sifo.
Imithombo ekhethiweyo
I-Article ethi "I-Hypothesis ye-Amyloid yeSifo se-Alzheimer: I-Progress and Promise Road to therapeutics" nguJ Hardy no-DJ Selkoe abashicilelwe kwiSayensi ngo-2002.
Ropper AH, Samuels MA, Klein JP. Isahluko 39. Izifo ezithintekayo kwiNkqubo yeNervous. Ku: Ropper AH, Samuels MA, Klein JP. eds. I-Adams ne-Victor's Principles of Neurology, 10e . New York, NY: McGraw-Hill; 2014. Kufumaneka ngoMatshi 22, 2015
I-Article ethi "Iimvavanyo eziphambili ze-ß-secretase inhibitors kwi-Alzheimer kaCormac Sheridan epapashwe kwi- Nature Biotechnology ngo-2015. Ukufikelela ngomhla we-3/22/2015.